Ironwood Pharmaceuticals Stock Price, News & Analysis (NASDAQ:IRWD)

$14.68 -0.15 (-1.01 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$14.68
Today's Range$14.50 - $15.03
52-Week Range$12.89 - $19.94
Volume791,236 shs
Average Volume1.55 million shs
Market Capitalization$2.22 billion
P/E Ratio-18.35
Dividend YieldN/A
Beta1.29

About Ironwood Pharmaceuticals (NASDAQ:IRWD)

Ironwood Pharmaceuticals logoIronwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases. It operates in human therapeutics business segment. Its product, linaclotide, is available to adult men and women suffering from IBS C or CIC in the United States under the trademarked name LINZESS, and is available to adult men and women suffering from IBS C in certain European countries under the trademarked name CONSTELLA. It is also advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled GERD. Its vascular/fibrotic programs include IW-1973 and IW-1701, which targets soluble guanylate cyclase (sGC).

Receive IRWD News and Ratings via Email

Sign-up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:IRWD
CUSIP46333X10
Phone617-621-7722

Debt

Debt-to-Equity Ratio-22.31%
Current Ratio4.87%
Quick Ratio4.86%

Price-To-Earnings

Trailing P/E Ratio-18.3497706278672
Forward P/E Ratio-32.62
P/E GrowthN/A

Sales & Book Value

Annual Sales$298.28 million
Price / Sales7.37
Cash FlowN/A
Price / CashN/A
Book Value$0.45 per share
Price / Book32.62

Profitability

Trailing EPS($0.80)
Net Income$-116,940,000.00
Net Margins-39.20%
Return on Equity-2,458.64%
Return on Assets-20.49%

Miscellaneous

Employees674
Outstanding Shares149,760,000

Ironwood Pharmaceuticals (NASDAQ:IRWD) Frequently Asked Questions

What is Ironwood Pharmaceuticals' stock symbol?

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

How were Ironwood Pharmaceuticals' earnings last quarter?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) issued its quarterly earnings results on Thursday, February, 15th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.18) by $0.04. The biotechnology company earned $94.20 million during the quarter, compared to analyst estimates of $88.86 million. Ironwood Pharmaceuticals had a negative net margin of 39.20% and a negative return on equity of 2,458.64%. Ironwood Pharmaceuticals's quarterly revenue was up 7.7% compared to the same quarter last year. During the same period last year, the business earned ($0.12) EPS. View Ironwood Pharmaceuticals' Earnings History.

When will Ironwood Pharmaceuticals make its next earnings announcement?

Ironwood Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Ironwood Pharmaceuticals.

Where is Ironwood Pharmaceuticals' stock going? Where will Ironwood Pharmaceuticals' stock price be in 2018?

10 analysts have issued twelve-month price targets for Ironwood Pharmaceuticals' shares. Their forecasts range from $13.00 to $21.00. On average, they expect Ironwood Pharmaceuticals' share price to reach $17.75 in the next twelve months. View Analyst Ratings for Ironwood Pharmaceuticals.

Who are some of Ironwood Pharmaceuticals' key competitors?

Who are Ironwood Pharmaceuticals' key executives?

Ironwood Pharmaceuticals' management team includes the folowing people:

  • Peter M. Hecht Ph.D., Chief Executive Officer, Director (Age 53)
  • Gina Consylman, Chief Financial Officer, Senior Vice President (Age 45)
  • William Huyett, Chief Operating Officer (Age 61)
  • Mark G. Currie Ph.D., Senior Vice President, Chief Scientific Officer, President - Research and Development (Age 62)
  • Thomas A. McCourt, Senior Vice President - Marketing and Sales, Chief Commercial Officer (Age 59)
  • Halley E. Gilbert Esq., Senior Vice President, Chief Legal Officer, Secretary (Age 47)
  • Christopher I. Wright M.D. Ph.D., Senior Vice President - Global Development and Chief Development Officer
  • Terrance G. McGuire, Non-Executive Independent Chairman of the Board (Age 61)
  • Andrew Dreyfus, Independent Director (Age 58)
  • Marsha H. Fanucci, Independent Director (Age 63)

Who owns Ironwood Pharmaceuticals stock?

Ironwood Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Brown Capital Management LLC (4.18%), Sarissa Capital Management LP (1.10%), Senzar Asset Management LLC (0.97%), Geode Capital Management LLC (0.83%), State of Wisconsin Investment Board (0.57%) and Clearbridge LLC (0.53%). Company insiders that own Ironwood Pharmaceuticals stock include Edward P Owens, Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht, Thomas A Mccourt and Thomas Graney. View Institutional Ownership Trends for Ironwood Pharmaceuticals.

Who sold Ironwood Pharmaceuticals stock? Who is selling Ironwood Pharmaceuticals stock?

Ironwood Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Artal Group S.A., Teachers Retirement System of The State of Kentucky, Macquarie Group Ltd., Metropolitan Life Insurance Co. NY, Guggenheim Capital LLC, Paloma Partners Management Co and Rhumbline Advisers. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Gina Consylman, Halley E Gilbert, Julie Mchugh, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Insider Buying and Selling for Ironwood Pharmaceuticals.

Who bought Ironwood Pharmaceuticals stock? Who is buying Ironwood Pharmaceuticals stock?

Ironwood Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Sarissa Capital Management LP, Senzar Asset Management LLC, Park West Asset Management LLC, Broderick Brian C, State of Wisconsin Investment Board, Chicago Equity Partners LLC, Fisher Asset Management LLC and Clearbridge LLC. View Insider Buying and Selling for Ironwood Pharmaceuticals.

How do I buy Ironwood Pharmaceuticals stock?

Shares of Ironwood Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ironwood Pharmaceuticals' stock price today?

One share of Ironwood Pharmaceuticals stock can currently be purchased for approximately $14.68.

How big of a company is Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals has a market capitalization of $2.22 billion and generates $298.28 million in revenue each year. The biotechnology company earns $-116,940,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Ironwood Pharmaceuticals employs 674 workers across the globe.

How can I contact Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]


MarketBeat Community Rating for Ironwood Pharmaceuticals (IRWD)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  293 (Vote Outperform)
Underperform Votes:  378 (Vote Underperform)
Total Votes:  671
MarketBeat's community ratings are surveys of what our community members think about Ironwood Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ironwood Pharmaceuticals (NASDAQ:IRWD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyHold
Consensus Rating Score: 2.302.272.502.44
Ratings Breakdown: 1 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $17.75$17.56$18.29$18.13
Price Target Upside: 16.78% upside15.50% upside22.56% upside21.48% upside

Ironwood Pharmaceuticals (NASDAQ:IRWD) Consensus Price Target History

Price Target History for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Ironwood Pharmaceuticals (NASDAQ:IRWD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/5/2018Bank of AmericaDowngradeBuy -> Underperform$20.00 -> $15.00HighView Rating Details
12/6/2017MizuhoDowngradeBuy -> Neutral$20.00 -> $16.00HighView Rating Details
12/4/2017Morgan StanleyReiterated RatingHoldHighView Rating Details
11/27/2017Credit Suisse GroupInitiated CoverageBuy$19.00MediumView Rating Details
8/21/2017CowenSet Price TargetBuy$20.00MediumView Rating Details
7/22/2017Wells Fargo & CoSet Price TargetBuy$19.00LowView Rating Details
7/21/2017Wood & CompanyDowngradeOverweight -> NeutralLowView Rating Details
7/21/2017JPMorgan Chase & Co.Reiterated RatingOverweight -> Neutral$20.00 -> $19.00HighView Rating Details
6/16/2017WedbushReiterated RatingNeutral$13.00LowView Rating Details
3/13/2017BTIG ResearchReiterated RatingBuy$18.00 -> $21.00LowView Rating Details
2/22/2017BarclaysReiterated RatingEqual Weight -> Equal Weight$13.00 -> $16.00N/AView Rating Details
9/27/2016WallachBeth CapitalBoost Price TargetHold$15.00 -> $17.00N/AView Rating Details
8/8/2016Leerink SwannReiterated RatingMarket Perform$10.00 -> $14.00N/AView Rating Details
4/28/2016JP Morgan CazenoveReiterated RatingOverweight$15.00N/AView Rating Details
3/21/2016Goldman Sachs GroupInitiated CoverageNeutral$14.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Ironwood Pharmaceuticals (NASDAQ:IRWD) Earnings History and Estimates Chart

Earnings by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Ironwood Pharmaceuticals (NASDAQ IRWD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018N/AView Earnings Details
2/15/2018Q4 2017($0.18)($0.14)$88.86 million$94.20 millionViewN/AView Earnings Details
11/2/2017Q3 2017($0.25)($0.18)$73.59 million$86.80 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.23)($0.28)$70.00 million$65.10 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.19)($0.33)$69.39 million$52.16 millionViewListenView Earnings Details
2/21/2017Q416($0.24)($0.12)$77.34 million$87.50 millionViewListenView Earnings Details
11/3/2016Q316($0.23)($0.18)$60.01 million$66.00 millionViewN/AView Earnings Details
8/4/2016Q216($0.15)($0.16)$54.49 million$54.40 millionViewN/AView Earnings Details
5/9/2016Q116($0.14)($0.08)$52.97 million$66.00 millionViewN/AView Earnings Details
2/18/2016Q415($0.17)($0.10)$44.78 million$53.30 millionViewListenView Earnings Details
11/3/2015Q315($0.20)($0.25)$39.81 million$39.60 millionViewListenView Earnings Details
8/5/2015Q215($0.22)($0.34)$36.08 million$27.74 millionViewN/AView Earnings Details
5/5/2015Q115($0.23)($0.24)$32.30 million$28.90 millionViewN/AView Earnings Details
2/12/2015Q414($0.21)($0.27)$35.20 million$38.10 millionViewListenView Earnings Details
11/4/2014Q314($0.32)($0.30)$21.20 million$16.90 millionViewListenView Earnings Details
8/4/2014Q214($0.36)($0.38)$15.75 million$6.84 millionViewListenView Earnings Details
4/29/2014Q1($0.45)($0.38)$8.52 million$14.60 millionViewListenView Earnings Details
1/21/2014Q413($0.50)($0.43)$7.13 million$5.00 millionViewListenView Earnings Details
10/22/2013Q313($0.57)($0.51)$6.54 million$4.90 millionViewN/AView Earnings Details
7/23/2013Q2 2013($0.70)($0.57)$6.32 million$9.70 millionViewN/AView Earnings Details
4/23/2013Q1 2013($0.71)($0.87)$8.94 million$3.30 millionViewN/AView Earnings Details
1/15/2013Q4 2012($0.49)($0.41)$16.17 million$27.00 millionViewN/AView Earnings Details
10/16/2012$0.17$0.42ViewN/AView Earnings Details
7/17/2012($0.31)($0.38)ViewN/AView Earnings Details
5/1/2012($0.23)($0.34)ViewN/AView Earnings Details
2/28/2012($0.11)($0.07)ViewN/AView Earnings Details
11/7/2011($0.20)($0.21)ViewN/AView Earnings Details
8/11/2011($0.18)($0.19)ViewN/AView Earnings Details
5/12/2011($0.17)($0.19)ViewN/AView Earnings Details
3/3/2011Q4 2010($0.13)($0.12)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.19)($0.16)ViewN/AView Earnings Details
8/5/2010Q2 2010($0.19)($0.18)ViewN/AView Earnings Details
5/11/2010Q1 2010($0.17)($0.25)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Ironwood Pharmaceuticals (NASDAQ:IRWD) Earnings Estimates

2018 EPS Consensus Estimate: ($0.30)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.11)($0.11)($0.11)
Q2 20181($0.09)($0.09)($0.09)
Q3 20181($0.06)($0.06)($0.06)
Q4 20181($0.04)($0.04)($0.04)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Ironwood Pharmaceuticals (NASDAQ:IRWD)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Ironwood Pharmaceuticals (NASDAQ IRWD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.63%
Insider Trades by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Ironwood Pharmaceuticals (NASDAQ IRWD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/21/2018Gina ConsylmanCFOSell3,594$14.66$52,688.0459,125View SEC Filing  
2/21/2018Mark G CurrieInsiderSell1,634$14.66$23,954.4418,124View SEC Filing  
1/24/2018Mark G CurrieInsiderSell60,000$15.45$927,000.00835,000View SEC Filing  
12/7/2017Peter M HechtCEOSell113,405$15.12$1,714,683.604,696,917View SEC Filing  
12/4/2017Julie MchughDirectorSell1,500$16.45$24,675.0079,408View SEC Filing  
11/10/2017Gina ConsylmanCFOSell864$15.20$13,132.80View SEC Filing  
9/5/2017Julie MchughDirectorSell1,500$16.16$24,240.0080,908View SEC Filing  
8/18/2017Gina ConsylmanInsiderSell207$14.34$2,968.3852,865View SEC Filing  
6/22/2017Halley E GilbertInsiderSell35,000$19.75$691,250.0035,000View SEC Filing  
5/15/2017Thomas A MccourtInsiderSell30,000$18.20$546,000.0030,000View SEC Filing  
2/14/2017Halley E GilbertInsiderSell37,385$16.75$626,198.7537,385View SEC Filing  
1/12/2017Peter M HechtCEOSell65,987$15.67$1,034,016.294,703,315View SEC Filing  
12/5/2016Lawrence S OlanoffDirectorSell3,200$15.68$50,176.0026,105View SEC Filing  
9/6/2016Lawrence S OlanoffDirectorSell3,200$13.72$43,904.0029,305View SEC Filing  
8/19/2016Gina ConsylmanInsiderSell207$13.54$2,802.7821,123View SEC Filing  
6/3/2016Lawrence S OlanoffDirectorSell2,200$12.92$28,424.0032,505View SEC Filing  
5/25/2016Halley E GilbertInsiderSell20,275$12.19$247,152.255,865View SEC Filing  
3/11/2016Peter M HechtCEOSell120,000$10.72$1,286,400.004,710,322View SEC Filing  
3/7/2016Lawrence S OlanoffDirectorSell2,200$11.11$24,442.0011,031View SEC Filing  
2/24/2016Edward P OwensDirectorBuy10,000$8.32$83,200.00144,006View SEC Filing  
2/24/2016Gina ConsylmanCAOSell420$8.50$3,570.006,330View SEC Filing  
2/24/2016Mark G CurrieInsiderSell152,154$8.53$1,297,873.6225,558View SEC Filing  
2/24/2016Thomas GraneyCFOSell563$8.50$4,785.505,137View SEC Filing  
12/15/2015Peter M. HechtCEOSell73,418$11.07$812,737.26View SEC Filing  
12/7/2015Lawrence S OlanoffDirectorSell2,200$11.77$25,894.0013,231View SEC Filing  
9/4/2015Lawrence S OlanoffDirectorSell3,725$10.97$40,863.2515,431View SEC Filing  
3/17/2015Peter M HechtCEOSell200,000$15.62$3,124,000.00View SEC Filing  
3/12/2015Joseph C Cook JrDirectorSell5,883$15.54$91,421.82View SEC Filing  
3/10/2015Bryan E RobertsDirectorSell95,998$15.20$1,459,169.60View SEC Filing  
3/3/2015Peter M HechtCEOSell63,442$15.75$999,211.50View SEC Filing  
2/20/2015Joseph C Cook JrDirectorSell35,500$15.60$553,800.00View SEC Filing  
12/15/2014Bryan E RobertsDirectorSell19,792$15.20$300,838.40View SEC Filing  
6/12/2014Bryan E RobertsDirectorSell200,000$14.24$2,848,000.00View SEC Filing  
5/29/2014Michael J HigginsCOOSell50,000$14.56$728,000.00View SEC Filing  
5/22/2014Mark CurrieInsiderSell25,000$13.93$348,250.002,166View SEC Filing  
4/24/2014Mark CurrieInsiderSell25,000$11.67$291,750.002,166View SEC Filing  
1/23/2014Mark CurrieInsiderSell20,000$14.38$287,600.002,166View SEC Filing  
1/14/2014Bryan RobertsDirectorSell21,200$12.57$266,484.00View SEC Filing  
1/13/2014Bryan RobertsDirectorSell823,350$12.71$10,464,778.50View SEC Filing  
1/6/2014Bryan RobertsDirectorSell55,450$12.01$665,954.50View SEC Filing  
11/7/2013Terrance McguireDirectorSell2,083$9.11$18,976.132,915View SEC Filing  
6/17/2013Michael J HigginsCOOSell150,000$11.74$1,761,000.00View SEC Filing  
3/11/2013Thomas A MccourtInsiderSell40,000$17.00$680,000.00View SEC Filing  
11/5/2012Peter M HechtCEOBuy50,000$11.65$582,500.00View SEC Filing  
10/8/2012Fmr LlcInsiderSell19,305$13.02$251,351.10View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ironwood Pharmaceuticals (NASDAQ IRWD) News Headlines

Source:
DateHeadline
State of Wisconsin Investment Board Has $12.69 Million Position in Ironwood Pharmaceuticals, Inc. (IRWD)State of Wisconsin Investment Board Has $12.69 Million Position in Ironwood Pharmaceuticals, Inc. (IRWD)
www.americanbankingnews.com - February 24 at 7:09 AM
Insider Selling: Ironwood Pharmaceuticals, Inc. (IRWD) Insider Sells 1,634 Shares of StockInsider Selling: Ironwood Pharmaceuticals, Inc. (IRWD) Insider Sells 1,634 Shares of Stock
www.americanbankingnews.com - February 22 at 7:26 PM
Ironwood Pharmaceuticals, Inc. (IRWD) CFO Sells $52,688.04 in StockIronwood Pharmaceuticals, Inc. (IRWD) CFO Sells $52,688.04 in Stock
www.americanbankingnews.com - February 22 at 7:08 PM
Ironwood (IRWD) Beats Estimates in Q4 Earnings, Stock UpIronwood (IRWD) Beats Estimates in Q4 Earnings, Stock Up
www.zacks.com - February 16 at 8:52 AM
Today’s Research Reports on Stocks to Watch: Ironwood Pharmaceuticals and Teva PharmaceuticalToday’s Research Reports on Stocks to Watch: Ironwood Pharmaceuticals and Teva Pharmaceutical
finance.yahoo.com - February 16 at 8:52 AM
Ironwood beats Street 4Q forecastsIronwood beats Street 4Q forecasts
finance.yahoo.com - February 15 at 4:50 PM
Ironwood Pharmaceuticals (IRWD) Posts Quarterly  Earnings ResultsIronwood Pharmaceuticals (IRWD) Posts Quarterly Earnings Results
www.americanbankingnews.com - February 15 at 11:40 AM
Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2017 Investor UpdateIronwood Pharmaceuticals Provides Fourth Quarter and Full Year 2017 Investor Update
finance.yahoo.com - February 15 at 8:30 AM
$86.24 Million in Sales Expected for Ironwood Pharmaceuticals, Inc. (IRWD) This Quarter$86.24 Million in Sales Expected for Ironwood Pharmaceuticals, Inc. (IRWD) This Quarter
www.americanbankingnews.com - February 15 at 3:34 AM
Ironwood Pharmaceuticals Inc’s (NASDAQ:IRWD) Earnings Dropped -73.31%, Did Its Industry Show Weakness Too?Ironwood Pharmaceuticals Inc’s (NASDAQ:IRWD) Earnings Dropped -73.31%, Did Its Industry Show Weakness Too?
finance.yahoo.com - February 14 at 9:24 AM
Ironwood Pharmaceuticals, Inc. (IRWD) Expected to Post Earnings of -$0.21 Per ShareIronwood Pharmaceuticals, Inc. (IRWD) Expected to Post Earnings of -$0.21 Per Share
www.americanbankingnews.com - February 13 at 11:14 PM
Ironwood Pharmaceuticals (IRWD) to Release Earnings on MondayIronwood Pharmaceuticals (IRWD) to Release Earnings on Monday
www.americanbankingnews.com - February 12 at 3:02 AM
Ironwood Pharmaceuticals (IRWD) Upgraded to Sell at BidaskClubIronwood Pharmaceuticals (IRWD) Upgraded to Sell at BidaskClub
www.americanbankingnews.com - February 11 at 6:22 AM
Ironwood Pharmaceuticals, Inc. (IRWD) Given Average Recommendation of "Hold" by AnalystsIronwood Pharmaceuticals, Inc. (IRWD) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - February 9 at 5:24 AM
Repros Therapeutics (RPRX) & Ironwood Pharmaceuticals (IRWD) Critical ComparisonRepros Therapeutics (RPRX) & Ironwood Pharmaceuticals (IRWD) Critical Comparison
www.americanbankingnews.com - February 5 at 10:24 AM
Wedbush Equities Analysts Reduce Earnings Estimates for Ironwood Pharmaceuticals, Inc. (IRWD)Wedbush Equities Analysts Reduce Earnings Estimates for Ironwood Pharmaceuticals, Inc. (IRWD)
www.americanbankingnews.com - February 2 at 9:08 AM
Brokers Set Expectations for Ironwood Pharmaceuticals, Inc.s FY2021 Earnings (IRWD)Brokers Set Expectations for Ironwood Pharmaceuticals, Inc.'s FY2021 Earnings (IRWD)
www.americanbankingnews.com - February 1 at 4:22 PM
Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2017 Investor Update CallIronwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2017 Investor Update Call
finance.yahoo.com - February 1 at 4:11 PM
$86.70 Million in Sales Expected for Ironwood Pharmaceuticals, Inc. (IRWD) This Quarter$86.70 Million in Sales Expected for Ironwood Pharmaceuticals, Inc. (IRWD) This Quarter
www.americanbankingnews.com - January 29 at 2:18 AM
Zacks: Analysts Expect Ironwood Pharmaceuticals, Inc. (IRWD) to Post -$0.18 EPSZacks: Analysts Expect Ironwood Pharmaceuticals, Inc. (IRWD) to Post -$0.18 EPS
www.americanbankingnews.com - January 27 at 11:16 PM
Mark G. Currie Sells 60,000 Shares of Ironwood Pharmaceuticals, Inc. (IRWD) StockMark G. Currie Sells 60,000 Shares of Ironwood Pharmaceuticals, Inc. (IRWD) Stock
www.americanbankingnews.com - January 26 at 9:10 PM
Interesting IRWD Put And Call Options For March 16thInteresting IRWD Put And Call Options For March 16th
www.nasdaq.com - January 25 at 4:12 PM
Today’s Research Reports on Trending Tickers: Aerie Pharmaceuticals and Ironwood PharmaceuticalsToday’s Research Reports on Trending Tickers: Aerie Pharmaceuticals and Ironwood Pharmaceuticals
finance.yahoo.com - January 25 at 9:24 AM
Wedbush Comments on Ironwood Pharmaceuticals, Inc.s FY2017 Earnings (IRWD)Wedbush Comments on Ironwood Pharmaceuticals, Inc.'s FY2017 Earnings (IRWD)
www.americanbankingnews.com - January 25 at 7:50 AM
Ironwood Pharmaceuticals, Inc. to Post FY2022 Earnings of $1.08 Per Share, Wedbush Forecasts (IRWD)Ironwood Pharmaceuticals, Inc. to Post FY2022 Earnings of $1.08 Per Share, Wedbush Forecasts (IRWD)
www.americanbankingnews.com - January 24 at 9:02 PM
Contrasting Ironwood Pharmaceuticals (IRWD) and Nektar Therapeutics (NKTR)Contrasting Ironwood Pharmaceuticals (IRWD) and Nektar Therapeutics (NKTR)
www.americanbankingnews.com - January 20 at 1:10 AM
Ironwood Pharmaceuticals (IRWD) Upgraded to "Hold" by Zacks Investment ResearchIronwood Pharmaceuticals (IRWD) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - January 18 at 9:56 PM
Ironwood and Allergan Announce Settlement with Sun Pharma Resolving LINZESS® (linaclotide) Patent LitigationIronwood and Allergan Announce Settlement with Sun Pharma Resolving LINZESS® (linaclotide) Patent Litigation
finance.yahoo.com - January 16 at 10:12 AM
Ironwood Pharmaceuticals, Inc. (IRWD) Given Consensus Recommendation of "Hold" by BrokeragesIronwood Pharmaceuticals, Inc. (IRWD) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 15 at 6:02 AM
Today’s Research Reports on Stocks to Watch: Agios Pharmaceuticals, Inc. and Ironwood Pharmaceuticals, Inc.Today’s Research Reports on Stocks to Watch: Agios Pharmaceuticals, Inc. and Ironwood Pharmaceuticals, Inc.
finance.yahoo.com - January 12 at 9:56 AM
Traders Buy Large Volume of Call Options on Ironwood Pharmaceuticals (IRWD)Traders Buy Large Volume of Call Options on Ironwood Pharmaceuticals (IRWD)
www.americanbankingnews.com - January 12 at 3:14 AM
Ironwood Pharmaceuticals, Inc. (IRWD) Expected to Announce Quarterly Sales of $81.30 MillionIronwood Pharmaceuticals, Inc. (IRWD) Expected to Announce Quarterly Sales of $81.30 Million
www.americanbankingnews.com - January 12 at 2:18 AM
Ironwood Pharmaceuticals, Inc. (IRWD) Expected to Post Earnings of -$0.22 Per ShareIronwood Pharmaceuticals, Inc. (IRWD) Expected to Post Earnings of -$0.22 Per Share
www.americanbankingnews.com - January 10 at 11:12 PM
Ironwood Pharmaceuticals (IRWD) Downgraded by Bank of AmericaIronwood Pharmaceuticals (IRWD) Downgraded by Bank of America
www.americanbankingnews.com - January 5 at 6:28 PM
Here's Why Ironwood Pharmaceuticals, Inc. Stock Slipped 13.2% in DecemberHere's Why Ironwood Pharmaceuticals, Inc. Stock Slipped 13.2% in December
finance.yahoo.com - January 4 at 3:28 PM
Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare ConferenceIronwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
finance.yahoo.com - January 2 at 8:40 PM
Ironwood Pharmaceuticals (IRWD) Rating Increased to Hold at ValuEngineIronwood Pharmaceuticals (IRWD) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - December 31 at 2:18 PM
Ironwood Pharmaceuticals (IRWD) Stock Rating Lowered by BidaskClubIronwood Pharmaceuticals (IRWD) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - December 30 at 2:54 PM
Ironwood Pharmaceuticals (IRWD) Cut to "Sell" at ValuEngineIronwood Pharmaceuticals (IRWD) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - December 29 at 9:26 PM
ETFs with exposure to Ironwood Pharmaceuticals, Inc. : December 26, 2017ETFs with exposure to Ironwood Pharmaceuticals, Inc. : December 26, 2017
finance.yahoo.com - December 26 at 12:51 PM
-$0.22 Earnings Per Share Expected for Ironwood Pharmaceuticals, Inc. (IRWD) This Quarter-$0.22 Earnings Per Share Expected for Ironwood Pharmaceuticals, Inc. (IRWD) This Quarter
www.americanbankingnews.com - December 25 at 11:38 AM
Head-To-Head Survey: Intellia Therapeutics (NTLA) versus Ironwood Pharmaceuticals (IRWD)Head-To-Head Survey: Intellia Therapeutics (NTLA) versus Ironwood Pharmaceuticals (IRWD)
www.americanbankingnews.com - December 23 at 3:36 PM
Ironwood Pharmaceuticals, Inc. :IRWD-US: Earnings Analysis: Q3, 2017 By the Numbers : December 22, 2017Ironwood Pharmaceuticals, Inc. :IRWD-US: Earnings Analysis: Q3, 2017 By the Numbers : December 22, 2017
finance.yahoo.com - December 22 at 9:35 AM
Sucampo Pharmaceuticals’ Amitiza: Its Competitive LandscapeSucampo Pharmaceuticals’ Amitiza: Its Competitive Landscape
finance.yahoo.com - December 22 at 9:35 AM
Stock Traders Purchase High Volume of Ironwood Pharmaceuticals Call Options (IRWD)Stock Traders Purchase High Volume of Ironwood Pharmaceuticals Call Options (IRWD)
www.americanbankingnews.com - December 22 at 4:06 AM
Ironwood Pharmaceuticals, Inc. (IRWD) Receives Consensus Recommendation of "Hold" from AnalystsIronwood Pharmaceuticals, Inc. (IRWD) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - December 21 at 5:38 AM
Ironwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IRWD-US : December 18, 2017Ironwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IRWD-US : December 18, 2017
finance.yahoo.com - December 18 at 9:17 AM
Ironwood Pharmaceuticals (IRWD) Rating Lowered to Hold at BidaskClubIronwood Pharmaceuticals (IRWD) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - December 9 at 2:24 PM
Zacks: Analysts Expect Ironwood Pharmaceuticals, Inc. (IRWD) Will Post Quarterly Sales of $81.30 MillionZacks: Analysts Expect Ironwood Pharmaceuticals, Inc. (IRWD) Will Post Quarterly Sales of $81.30 Million
www.americanbankingnews.com - December 9 at 4:30 AM
Ironwood Pharmaceuticals, Inc. (IRWD) CEO Sells $1,714,683.60 in StockIronwood Pharmaceuticals, Inc. (IRWD) CEO Sells $1,714,683.60 in Stock
www.americanbankingnews.com - December 8 at 5:30 PM

SEC Filings

Ironwood Pharmaceuticals (NASDAQ:IRWD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ironwood Pharmaceuticals (NASDAQ:IRWD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ironwood Pharmaceuticals (NASDAQ IRWD) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.